Get the Stockscreener App
0.2798
2.00%
-0.0057
After Hours:
29.72
29.44
+10,522%
Relmada Therapeutics Inc stock is traded at $0.2798, with a volume of 323.49K.
It is down -2.00% in the last 24 hours and down -28.11% over the past month.
Relmada Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in developing chemical entities with novel versions of drug products that address areas of high unmet medical need in the treatment of central nervous system diseases. The company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Its lead product candidate, esmethadone, is an oral agent for the treatment of depression and other potential indications.
See More
Previous Close:
$0.2855
Open:
$0.2813
24h Volume:
323.49K
Relative Volume:
0.21
Market Cap:
$8.44M
Revenue:
-
Net Income/Loss:
$-98.79M
P/E Ratio:
-0.0856
EPS:
-3.27
Net Cash Flow:
$-51.66M
1W Performance:
-15.60%
1M Performance:
-28.11%
6M Performance:
-89.90%
1Y Performance:
-95.07%
1-Day Range:
$0.2603
$0.2899
1-Week Range:
$0.2603
$0.3373
52-Week Range:
$0.2603
$7.2225
Relmada Therapeutics Inc Stock (RLMD) Company Profile
Name
Relmada Therapeutics Inc
Sector
Industry
Phone
646 876 3459
Address
2222 PONCE DE LEON BLVD. 3RD FLOOR, CORAL GABLES, NY
Compare RLMD with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
| 3.03 | 0 | 0 | 0 | 0 | 0.00 | |
PSNYW
Polestar Automotive Holding Uk
|
0.1935 | 408.35M | 2.07B | -1.42B | -1.37B | -0.6765 |
|
GOODO
Gladstone Commercial Corporation
|
20.50 | 372.90M | 0 | 0 | 0 | 0.00 |
|
MOBBW
Mobilicom Limited Warrants
|
0.4399 | 278.60M | 0 | 0 | 0 | 0.00 |
|
SHMD
Schmid Group N V
|
2.79 | 120.14M | 0 | 0 | 0 | 0.00 |
|
JUNE
Dhandho Junoon Etf
|
4.0439 | 52.60M | 0 | 0 | 0 | 0.00 |
Relmada Therapeutics Inc Stock (RLMD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-05-24 | Downgrade | Mizuho | Outperform → Neutral |
| Sep-17-24 | Upgrade | Jefferies | Hold → Buy |
| Jun-05-24 | Downgrade | Goldman | Neutral → Sell |
| Oct-14-22 | Downgrade | Goldman | Buy → Neutral |
| Oct-14-22 | Downgrade | Guggenheim | Buy → Neutral |
| Oct-14-22 | Downgrade | Truist | Buy → Hold |
| Oct-13-22 | Downgrade | Oppenheimer | Outperform → Perform |
| Nov-18-21 | Initiated | Mizuho | Buy |
| May-20-21 | Resumed | Goldman | Buy |
| Oct-28-20 | Downgrade | Goldman | Buy → Neutral |
| Jul-14-20 | Initiated | Oppenheimer | Outperform |
| May-04-20 | Initiated | SunTrust | Buy |
| Apr-21-20 | Initiated | Goldman | Buy |
| Jan-27-20 | Initiated | Jefferies | Buy |
| Jan-10-20 | Initiated | SVB Leerink | Outperform |
| Dec-16-19 | Initiated | Guggenheim | Buy |
View All
Relmada Therapeutics Inc Stock (RLMD) Latest News
Comprehensive Market Analysis of Latest Published Different Types of Depression Reports | DelveInsight - GlobeNewswire Inc.
RLMD stock touches 52-week low at $0.28 amid market challenges - Investing.com Australia
A significant driver of top-line growth: Relmada Therapeutics Inc (RLMD) - SETE News
Relmada acquires new Tourette syndrome treatment asset - MSN
Relmada Therapeutics Inc [RLMD] Investment Guide: What You Need to Know - Knox Daily
RLMD stock’s current quarter earnings estimates: What analysts predict? - US Post News
Closing Strong: Relmada Therapeutics Inc (RLMD) Ends at 0.31, Down -9.62 from Last Close - The Dwinnex
Relmada Therapeutics Inc’s Shares Reel: -90.69% Quarterly Revenue Decline Amid 9.33M Market Cap - The InvestChronicle
A company insider recently bought 51,407 shares of Relmada Therapeutics Inc [RLMD]. Should You Buy? - Knox Daily
Mizuho maintains Neutral on Relmada stock, sees deal potential - MSN
The Tourette’s Deal That Came Too Late To Save Sweden’s Asarina - News & Insights
Relmada in-licenses Tourette syndrome drug from Asarina - The Pharma Letter
Take off with Relmada Therapeutics Inc (RLMD): Get ready for trading - SETE News
Relmada acquires Tourette’s therapy rights from Asarina - Yahoo Finance
Lipella Pharmaceuticals Inc [LIPO] Revenue clocked in at $0.48 million, up 52.46% YTD: What’s Next? - The DBT News
Relmada acquires new Tourette syndrome treatment asset By Investing.com - Investing.com Nigeria
Mizuho maintains Neutral on Relmada stock, sees deal potential By Investing.com - Investing.com Australia
Relmada Therapeutics Acquires Sepranolone From Asarina Pharma For Potential TS Treatment - Nasdaq
Relmada Therapeutics Acquires Potential Therapy for Tourette Syndrome from Asarina Pharma AB - Marketscreener.com
Relmada Therapeutics acquires Sepranolone from Asarina Pharma - TipRanks
Relmada Therapeutics (RLMD) Acquires Potential Therapy for Tourette Syndrome from Asarina Pharma AB - StreetInsider.com
Groundbreaking Tourette Treatment Shows 69% QoL Improvement in Clinical TrialRelmada's Latest Acquisition - StockTitan
Relmada Therapeutics Acquires Sepranolone for CNS Portfolio - TipRanks
Relmada Therapeutics Inc (RLMD) Stock: Navigating a Year of Volatility - The InvestChronicle
Relmada Therapeutics Acquires Potential Therapy For Tourette Syndrome From Asarina Pharma AB - Marketscreener.com
A stock that deserves closer examination: Relmada Therapeutics Inc (RLMD) - US Post News
Relmada Therapeutics Inc (RLMD) may enjoy gains as insiders got busy in the recent days - Knox Daily
Investor’s Delight: Relmada Therapeutics Inc (RLMD) Closes Weak at 0.34, Down -2.61 - The Dwinnex
RLMD stock touches 52-week low at $0.34 amid sharp annual decline - Investing.com Canada
Relmada Therapeutics Inc (NASDAQ:RLMD) Has Made The 2.86% Recovery, Could Gain Another -1962.86% Ahead - Marketing Sentinel
Relmada Therapeutics (NASDAQ:RLMD) Receives Notification from Nasdaq Regarding Minimum Bid Price Compliance - Defense World
Relmada Therapeutics faces potential Nasdaq delisting - MSN
Geode Capital Management LLC Increases Stake in Relmada Therapeutics, Inc. (NASDAQ:RLMD) - Defense World
Relmada appoints new COO, freezes executive pay - Investing.com
Relmada appoints new COO, freezes executive pay By Investing.com - Investing.com UK
Relmada Therapeutics Appoints COO and Updates Executive CompensationRELMADA THERAPEUTICS, INC. (NASDAQ: RLMD) recently announced a significant update regarding its leadership team and executive compensation structure. According to a rec - Defense World
Relmada Therapeutics Strengthens Leadership with New COO - TipRanks
US Penny Stocks To Watch In January 2025 - Simply Wall St
RLMD stock touches 52-week low at $0.35 amid market challenges - Investing.com Canada
Relmada Therapeutics to Report Third Quarter 2021 Financial Results and Host Conference Call and Webcast on November 11, 2021 - BioSpace
Relmada stock hits 52-week low at $0.43 amid market challenges - Investing.com Australia
Relmada stock hits 52-week low at $0.43 amid market challenges By Investing.com - Investing.com South Africa
Relmada seeking strategic options, stock climbs 5% - MSN
Kuehn Law Encourages Investors of Relmada Therapeutics, Inc. to Contact Law Firm - The Eastern Progress Online
Relmada Therapeutics Inc Stock (RLMD) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.53%
0.33%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):